FDA Approves Pfizer's and Eisai's FRAGMIN(R) as First Low-Molecular-Weight Heparin for Extended Treatment to Reduce the Recurrence of Blood Clots in Patients with Cancer WOODCLIFF LAKE, N.J. and NEW ...

Pfizer won the backing of a US Food and Drug Administration advisory panel yesterday to extend the use of its anti-clotting drug Fragmin to include the prevention of venous thromboembolism (VTE) in ...

The drug was initially approved by the FDA in 1994 for adults and is a type of heparin. The US Food and Drug Administration has approved Pfizer’s Fragmin (dalteparin sodium) injection to reduce the ...

The FDA has approved Fragmin, a low molecular weight heparin, for the treatment of symptomatic venous thromboembolism to reduce the recurrence of VTE in pediatric patients 1 month of age and older.